Skip to content
Open access

Risk factors for low-level viremia and virological failure in HIV patients in southwestern China who transitioned to second-line antiretroviral therapy after failure of first-line treatment: a retrospective cohort study

Oct 2026 · Frontiers in Public Health · Vol 14 · 0 citations · 41 references
Medicine

TL;DR

Enhanced monitoring of resistance markers and immunological indicators is warranted among patients receiving second-line ART to facilitate timely clinical evaluation and treatment adjustment in resource-limited settings.

Abstract

Objective To investigate factors associated with low-level viremia (LLV) and virological failure (VF) in HIV patients who transitioned to second-line antiretroviral therapy (ART) after first-line ART failure, aiming to inform management strategies for virological fluctuations among second-line ART patients in resource-limited settings. Methods This retrospective cohort study included HIV patients who switched to second-line ART regimens between January 1, 2000, and January 1, 2026, due to first-line ART failure. Baseline demographic data (e.g., age at diagnosis, sex) and clinical indicators (e.g., time from diagnosis to ART initiation, baseline viral load, baseline CD4+ T lymphocyte count) at enrollment were collected. LLV and VF were defined as outcomes. Cox proportional hazards regression models were used to evaluate the associations between baseline characteristics/clinical indicators and LLV and VF. Results A baseline CD4+ T lymphocyte count ≥350 was associated with a lower hazard of both LLV (aHR, 0.82; 95% CI: 0.60–0.88) and VF (aHR, 0.49; 95% CI: 0.29–0.76). HIV infection through homosexual transmission was associated with a higher hazard of LLV (aHR, 3.69; 95% CI: 1.48–9.23). Use of DTG + 3TC + TDF as a second-line regimen was associated with a higher hazard of both LLV (aHR, 2.25; 95% CI: 1.31–5.82) and VF (aHR, 2.23; 95% CI: 1.32–3.25). Co-infection with hepatitis B was associated with a higher hazard of LLV (aHR, 2.12; 95% CI: 1.13–6.23), whereas HCV seropositivity was associated with a higher hazard of both LLV (aHR, 3.01; 95% CI: 1.78–7.48) and VF (aHR, 2.79; 95% CI: 1.52–6.14). The M184V mutation was associated with a higher hazard of LLV (aHR, 6.35; 95% CI: 1.44–27.93). Both M184V (aHR, 4.76; 95% CI: 1.02–19.63) and K103N (aHR, 10.00; 95% CI: 4.12–24.30) mutations were associated with a higher hazard of VF. Conclusion Lower baseline CD4+ T lymphocyte count, HIV infection through homosexual transmission, use of DTG + 3TC + TDF as a second-line regimen, hepatitis B co-infection or HCV seropositivity, and the presence of specific resistance-associated mutations were associated with a higher hazard of LLV and VF. Therefore, enhanced monitoring of resistance markers and immunological indicators is warranted among patients receiving second-line ART to facilitate timely clinical evaluation and treatment adjustment.

Read PDF

Similar papers

Open access Oct 2026

Predictors of Virologic Failure Among Adults with Low-Level Viremia: A Retrospective Cohort Study in Oromia, Ethiopia

A retrospective cohort study among adults with at least one LLV episode documented between October 2023 and June 2025 across 105 health facilities in Oromia, Ethiopia and evaluated predictors of progression from LLV to virologic failure and characterized the time-dependent probability of progression in a large Ethiopia...

Lamessa Tadesse Amante, Muluembet Abera Wordofa · 0 citations
Open access Nov 2026

HIV/AIDS patients with low-level viremia in different states have variable risks of subsequent viral suppression failure: a large retrospective study in Chongqing

To analyze the basic characteristics and influencing factors of low-level viremia (LLV) among treated HIV/AIDS patients in Chongqing and to examine the association between low-level viremia and virological failure. Data from AIDS patients who were diagnosed and treated at the Chongqing Public Health Medical...

Yong-Jian Fu, Kun He, Qian Liu et al. · 0 citations
Open access Sep 2026

Genotype-guided antiretroviral therapy outcomes in routine clinical practice: a retrospective study of HIV viral load suppression at 6 and 12 months in Uganda.

This study assessed virological outcomes following genotype-guided antiretroviral therapy (GART). We conducted a retrospective cohort of 235 PLHIV (2021-2023) post-GART after virological failure, analyzing baseline characteristics, 6- and 12-month viral load outcomes, and suppression factors using descriptive statistic...

Collins Ankunda, Jude Emunyu, S. Namasambi et al. · 0 citations
Open access Oct 2026

First-Line Antiretroviral Regimens and Risk of Incident Hypertension in People With HIV: A 15-Year Cohort Study

Abstract Background People with HIV (PWH) face a growing burden of cardiovascular disease. Integrase strand transfer inhibitors (INSTIs) have been linked to weight gain and possibly hypertension, but head-to-head data among contemporary regimens are scarce, and few studies analyze older and modern regimens together. We...

J. I. Bernardino, C. Busca, L. Serrano et al. · 0 citations
Open access Jan 2026

Nonoptimal Virological Response Among Adults Living With HIV After Initiation of Combined Antiretroviral Therapy at a Tertiary Hospital in Oman: A Retrospective Cohort Study, 1992–2024

Background Combined antiretroviral therapy (cART) has transformed HIV infection from a life‐threatening condition into a manageable chronic disease by reducing viral replication, preserving immune function, and lowering HIV‐related morbidity and mortality. Nevertheless, achieving and maintaining viral suppression remai...

Zainab M. Al-Zadjali, Faryal Khamis, Sanjay Jaju et al. · 0 citations
Open access Oct 2026

Low Prevalence of HIV-1 Antiretroviral Resistance Among Patients Experiencing Virological Failure on Dolutegravir-Based Regimens: A Prospective Cohort Study in Bunia, Democratic Republic of the Congo

The adoption and widespread use of dolutegravir (DTG)-based antiretroviral therapy (ART) are key strategies for achieving global 2030 targets, though emerging resistance threatens long-term success. This study evaluated HIV-1 drug resistance mutations among participants experiencing virological failure in Bunia, Democr...

Alex Liripa Kwendra, A. Mouinga-Ondémé, J. Engone-Ondo et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.